Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Assets (2016 - 2025)

Cytokinetics (CYTK) has disclosed Non-Current Assets for 16 consecutive years, with $507.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets changed N/A to $507.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 billion, a N/A change, with the full-year FY2025 number at $507.6 million, changed N/A from a year prior.
  • Non-Current Assets was $507.6 million for Q4 2025 at Cytokinetics, up from $459.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $507.6 million in Q4 2025 to a low of $143.9 million in Q1 2021.
  • A 5-year average of $275.3 million and a median of $219.6 million in 2022 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 497.12% in 2021, then crashed 42.37% in 2022.
  • Cytokinetics' Non-Current Assets stood at $305.6 million in 2021, then dropped by 28.16% to $219.6 million in 2022, then dropped by 10.62% to $196.3 million in 2023, then soared by 112.7% to $417.5 million in 2024, then grew by 21.58% to $507.6 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Non-Current Assets are $507.6 million (Q4 2025), $459.2 million (Q3 2025), and $339.1 million (Q2 2025).